What is The Distrio?
The Distrio helps clients in the heavily-regulated cannabinoid supply chain achieve compliant revenue faster.
As a Supply Chain Accelerator, we focus on product commercialization through regulatory and technical support across the seed-to-sales cycle.
Our commercial, technical, and regulatory expertise, married with our strong focus on technology, has led to a number of leading innovations including Vanna, our Quality Audit Assistant, and Mikey, our CoA Specialist - all built on DistrioGPT.
TUNE INTO @TheDalesReport AT 4:25PM EST
Harv Johal (CRO) and Sean Karl (PM) explain how countries like Australia, Germany, Israel, and parts of Europe treat CBD APIs, GMP manufacturing and pharmacy distribution much differently than the U.S. market.
(link below)
If you want to understand *precisely* how cannabinoids can provide great value within America's healthcare system, have a listen to Dr. Paul Shields from @vantagehemp speaking passionately on
@TheDalesReport
Tune in at 40 minutes and learn why healthcare operators, pharmacy leaders, and accountable care organizations are paying attention to Dr. Shields
https://t.co/vCJ0NkrPNc
TODAY @ 4PM EST - Rusty Kuchta and Dr. Paul Shields join The Dales Report to discuss:
• The Medicare Substance Access BEI Pilot
• Neuropathic Pain Optimization Pathways
• CBD as a value-based healthcare intervention
Watch live @TheDalesReport#CBD#Healthcare#Medicare
We are huge fans of Dr. Paul Shields.
Dr. Shields is passionately committed to understanding and proving the value of cannabis-based medicines in healthcare settings.
With the Medicare CBD pilot about to kick off, this appointment will allow @vantagehemp to set the standard for clinicians and cannabinoid therapies.
#cannabidiol #ACOs #Medicare
Dr. Paul Shields joins Vantage Hemp as CMO to lead strategy for the emerging Medicare CBD pilot.
• REACH ACO + oncology pathway expertise
• Clinical governance + formulary design
• Pharma-grade, DMF-backed CBD APIs
Dr. Shields will drive execution inside value-based care.
President Donald Trump’s recent executive order rescheduling cannabis to a Schedule III controlled substance marks the most momentous shift in U.S. federal drug policy since 1970.
We used DistrioGPT to produce a deep dive report on what this means for pharmaceutical grade CBD producer, Vantage Hemp Co.
If you are curious about the potential changes to cannabis regulation in the United States, this report is a helpful resource. (Link in reply)
"Sources familiar with the administration’s planning tell Marijuana Moment that an announcement on the rescheduling is planned for 1:30pm ET and that Trump will be surrounded by various cannabis industry and movement stakeholders when signing the order." https://t.co/q8Q8NUU5WD
Have you noticed the massive uptick in Reefer Madness media the past few weeks? From 'scromiting' to 'no medicinal value', we can see the not-so-invisible hand of the anti-cannabis lobby.
So who, exactly, is in that room? DistrioGPT's Guy Fontaine has a deep dive for you
1/
When someone shares a COA with Mikey, he will validate that COA against your official template(s) in his vector store to ensure it has not been tampered with. This is a completely free service that protects your clients.
Join our fraud detection program:
https://t.co/ACHiBPwSH1
Mikey is our AI assistant designed to assess Certificates of Analysis (COAs) for authenticity, reliability, and suitability across various global markets.
As part of Mikey's fraud detection training at The Distrio, we are building a vector database of official COA templates and authorized signatories from ISO/IEC 17025 licensed cannabis testing laboratories.
1/🧵
Not sure if this was a QA slip-up, or a commercial decision manifesting as a QA slip-up, but not having a moisture pack in the 14g bags of @RedecanCannabis has definitely impacted bud quality.
#SpaceAgeCake#cannabisculture